<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757989</url>
  </required_header>
  <id_info>
    <org_study_id>MDS-ALLO-RISK</org_study_id>
    <secondary_id>2015-A00292-47</secondary_id>
    <nct_id>NCT02757989</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk</brief_title>
  <official_title>Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM &amp; SFGM-TC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of survival in patients with or without a matched donor at 36 months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)&#xD;
      received an allogeneic hematopoietic stem cell transplantation.&#xD;
&#xD;
      Patients without a matched donor received the best available treatment. All patients will be&#xD;
      followed at least 36 months or until the end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 31, 2016</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>comparison of overall survival in patients with or without a matched donor (8/8 unrelated donor or matched sibling) at 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>comparison of quality of life in patients with or without a matched donor, quality of life assessed by questionnaire (EORTC version 3) at inclusion, 12, 24 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with complete response at 36 month</measure>
    <time_frame>36 months</time_frame>
    <description>comparison between patients with or without a donor for cumulative incidence of complete response at 36 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with transformation in AML at 36 month</measure>
    <time_frame>36 months</time_frame>
    <description>comparison between patients with or without a donor for cumulative incidence of transformation in AML at 36 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with iron overload</measure>
    <time_frame>16 months</time_frame>
    <description>proportion of patients with iron overload (Serum Ferritin (SF)&gt;1000 ng/mL or Red Blood Cells transfusion&gt;20) at time of inclusion and at 16 month after inclusion for non-transplanted patients and 12 months post-transplant for transplanted patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of innovative iron markers including Non-transferrin binding iron (NTBI), labile plasmatic Iron (LPI) and Hepcidine</measure>
    <time_frame>3 and 16 months</time_frame>
    <description>evolution of innovative iron markers including Non-transferrin binding iron (NTBI), labile plasmatic Iron (LPI) and Hepcidine measured at time of inclusion, at 3 month and 16 month post-inclusion for all patients; In transplanted patients these markers will be measured just before conditioning regimen (J-5), Just before the transplantation (J0), at D7, 30, 100 and 12 month after transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficiency of chelation</measure>
    <time_frame>3 and 16 months</time_frame>
    <description>the effect of chelation will be assessed at 3 month after inclusion for all patient and post transplant by measuring Serum ferritin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with adverse events grade III and IV as assessed by CTCAE v4.0</measure>
    <time_frame>36 months</time_frame>
    <description>comparison between patients with or without a donor for number of Grade III and IV toxicities (hematological and non-hematological) recorded according to NCI CTCAE criteria versions 4.0 during the 36 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>Patients with donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without donor</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients without a matched donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>transplantation</intervention_name>
    <description>allogeneic hematopoietic stem cell transplantation in patients with donor</description>
    <arm_group_label>Patients with donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed consent&#xD;
&#xD;
          2. Classical IPSS intermediate 1 or low myelodysplastic syndrome associated with at least&#xD;
             one poor prognosis feature:&#xD;
&#xD;
               1. Intermediate or higher risk revised IPSS&#xD;
&#xD;
               2. RBC transfusion dependent anemia and failure to 2 or more lines or therapy&#xD;
                  (including EPO, Lenalidomide or demethylating agent…)&#xD;
&#xD;
               3. thrombocytopenia &lt; 20 G/L requiring transfusion&#xD;
&#xD;
               4. neutropenia &lt; 0.5 G/L associated with severe infection (defined as requiring&#xD;
                  hospitalization)&#xD;
&#xD;
          3. Patient aged ≥ 18 and &lt; 70 years For young patients, 18-45 years, Fanconi disease and&#xD;
             dyskeratosis should be ruled out&#xD;
&#xD;
          4. Patient for whom a transplantation from a matched donor, (8/8 (HLA A, B, C, DRB1)&#xD;
             identical at molecular level)unrelated donor or matched sibling), is considered&#xD;
             irrespective of donor availability&#xD;
&#xD;
          5. Performance status 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale (At time&#xD;
             of screening)&#xD;
&#xD;
          6. Negative pregnancy and adequate contraception (including in male patients wishing to&#xD;
             father), if relevant.&#xD;
&#xD;
          7. Wash-out of at least 30 days since a previous treatment with Vidaza, Lenalidomide, EPO&#xD;
             or any other treatment inducing cytopenias.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MDS classified according to classical IPSS as intermediate 2 or High risk&#xD;
&#xD;
          2. Transformation in Acute myeloid Leukemia (AML)&#xD;
&#xD;
          3. Severe active infection or any other uncontrolled severe condition.&#xD;
&#xD;
          4. Organ dysfunctions including the following&#xD;
&#xD;
               -  Hepatic : total bilirubin &gt; 2 times upper limit of normal (ULN) (except moderate&#xD;
                  unconjugated hyperbilirubinemia due to intra medullary hemolysis or Gilbert&#xD;
                  syndrome) , alanine transaminase (ALT) and aspartate transaminase (AST) &gt; 3xULN&#xD;
&#xD;
               -  Symptomatic respiratory chronic failure&#xD;
&#xD;
               -  Symptomatic cardiac failure&#xD;
&#xD;
               -  Renal clearance &lt; 60ml/min&#xD;
&#xD;
          5. Prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, or&#xD;
             other tumors if not active during the last 3 years)&#xD;
&#xD;
          6. MDS with the following causal germline disease : Fanconi anemia, GATA2 related&#xD;
             syndromes and telomere disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Robin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Haut Lévèque</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHSF Gilles de Corbeil</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHEF, site de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCT-Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Brabois</name>
      <address>
        <city>Vandoeuvre les nancy</city>
        <zip>54550</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low risk MDS</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

